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Abstract
Osteoarthritis is a degenerative condition of synovial joints that result in pain and 
decreased level of function. This is a leading cause of disability in the United 
States, with disease of the knee being most common. Current non-surgical 
treatment options focus on symptomatic management and are associated with 
unfavorable side effect profiles. The purpose of this study is to compare the 
efficacy of two intra-articular injections, hyaluronic acid and platelet rich plasma. 
After a systematic literature search was performed, 7 articles met criteria for 
evaluation. When comparing the treatment options, both were shown to 
significantly improve symptoms from baseline, however a statistically significant 
difference between the options was not observed. Further research is needed before 
changes to clinical practice can be recommended. 
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Overview of Osteoarthritis:
• Degenerative disease of synovial joints1
• A leading cause of disability in the US2
• Affects ~27 million people in US, with 14 million having disease of the knee3,4
Clinical Presentation:
• Joint pain, swelling, and stiffness that is worse with activity5
Diagnosis:
• X Ray images 
• Kellgren-Lawrence grading system6
Treatment Options:
• Lifestyle modifications and weight loss 
• NSAIDs or Acetaminophen7
• Intra-articular corticosteroid injections8
• Intra-articular hyaluronic acid injections8,9




Search Engines used in October 2019:
• PubMed 
• EBSCO Host 
Search Terms:
• “(platelet rich plasma OR PRP) AND (hyaluronic acid OR HA) AND pain 
AND (knee osteoarthritis OR KOA)
Inclusion Criteria:
• PRP compared to HA 
• Knee osteoarthritis
• Pain scale assessments were used to evaluate treatment
• Intra-articular injections 
• Human studies
• Free with Arcadia University access 
• Published from 2014-2019
Due to the high prevalence and economic burden of knee 
osteoarthritis, making advances in therapeutic options is 
pivotal. As standard treatment options focus on symptomatic 
relief and are associated with adverse effects, novel platelet 
rich plasma intra-articular injections show promise with the 
possibility of altering disease progression. This option was 
compared to hyaluronic acid intra-articular injections as these 
injections are an accepted last line of treatment before 
considering knee arthroplasty. 6 out of the 7 evaluated studies 
were randomized controlled trials that compared PRP and HA 
directly with quality-of-life questionnaires as the primary 
outcome. With regard to study duration, a timepoint of 6 
months was used for 4 studies, and 12 months for 3 studies. 
Significance was established as p<0.05 for all studies with the 
outcome of PRP producing greater symptomatic relief than 
HA. All of the evaluated studies saw significant improvements 
in symptoms from their respective baseline, however no 
conclusive differences between PRP or HA treatment groups 
was observed.
Limitations: 
• All studies used a different combination of questionnaires 
• Limited study duration 
• Non-standardized treatment protocols 
Focus of future studies:
• Extended follow up period 
• Standardized set of questionnaires 
• Standardized treatment protocols 
DiscussionResults
Title: Comparing the efficacy of intra-articular injections of platelet rich plasma 
and hyaluronic acid in the treatment of Kellgren Lawrence stage I-III Knee 
Osteoarthritis 
After evaluation of the 7 included articles, it can be concluded 
that PRP and HA are both effective treatment options to relieve 
symptoms of knee osteoarthritis for a duration of at least 6 
months. At this point, the data fails to show a superiority of 
either treatment, and outcomes were similar for both groups. 
As both treatment options have been proven safe with no 
serious adverse effects in any of the included trials, further 
research needs to be conducted with more standardized 
treatment protocols and outcome measures over a longer 
duration. The data is insufficient to suggest a change to clinical 
practice at this time. 
Conclusion









Heredia E.,  
et al.10
RCT 53 M = 21, FM = 32, stage 
I = 7, stage II = 19, 
stage III = 27 
Stage     I-III PRP vs. HA 
vs.metamizole/parace
tamol and ibuprofen 
3 injections 15 
days apart for 
both 






RCT 99 M = 48, FM = 51, stage 
I = 3, stage II = 53, 
stage III = 42, unknown 
= 1  
Stage I-III PRP vs. HA 3 injections 7 
days apart for 
both 
52 weeks post 
treatment  
WOMAC; IKDC; 




RCT 102 M = 6, FM = 96, stage II 
= 69, stage III = 33 
Stage II-III PRP vs. HA vs. 
Ozone gas 
2 injections of 
PRP; 1 injection 
of HA; 4 
injections of 
ozone gas





RCT 183 M = 112, FM = 71 Stage I-III PRP vs. HA 3 injections 7 
days apart for 
both 






Retrospective 132 M = 21, FM = 111, stage 
I = 51, stage II = 81 
Stage I – II PRP vs. HA 3 injections 7 
days apart for 
both 






RCT 89 M = 28, FM = 61, stage 
I = 15, stage II = 36, 
stage III = 38 
Stage I – III PRP vs. HA 3 injections 14 
days apart for 
both 






RCT 34 Gender differences not 
known after final 
exclusion, M = 25, FM 
= 23 at point of intent to 
treat. 
Stage >2 PRP vs. HA Single injection 
of both 
6 months post 
treatment 
WOMAC; VAS 
Table 1: Comparison of study design for platelet rich plasma intra-articular injections vs. hyaluronic acid intra-articular injections. 
Table 1 Key: RCT = randomized controlled trial; M = male; FM = female; PRP = platelet rich plasma; HA = hyaluronic acid; VAS = visual analog scale; KOOS = knee and osteoarthritis 
outcome system; EUROQOL = european quality of life scale; OA = osteoarthritis; K-L = kellgren-lawrence; WOMAC = western Ontario and McMaster universities osteoarthritis index; 
IKDC = international knee documentation committee; EQ-VAS = EuroQol visual analog scale; KSS = Knee Society’s Knee Scoring System 
Table 2: Summary of end results comparing intra-articular platelet rich plasma injections to hyaluronic acid injections. 
Study WOMAC IKDC VAS Lysholm KOOS EURO-QOL Tegner EQ-VAS KSS
Montañez-
Heredia E.,  
et al.10
- - NS - NS NS - - -
Cole, B.J., et 
al.11
NS S S NS - - - - -
Duymus
T.M., et al.12
S - S - - - - - -
Filardo, G., 
et al.13
- NS - - NS - NS NS -
Guler, O., et 
al. 14
- - NS - - - - - S
Ahmad, 
H.S., et al.15
- S S - - - - -
Louis, M.L., 
et al.16
NS - NS - - - - -
Table 2 Key: WOMAC = western Ontario and McMaster university osteoarthritis index; IKDC = international knee documentation committee; VAS = visual 
analog scale; KOOS = = knee and osteoarthritis outcome system; EUROQOL = european quality of life scale; EQ-VAS = EuroQol visual analog scale; S = 
significant;  NS = not significant; - = measure was not used; KSS = Knee Society’s Knee Scoring System
WOMAC IKDC VAS Lysholm KOOS EUROQOL Tegner EQ-VAS KSS
S = PRP showed greater 
reduction in pain than 
HA (P<0.05) 
NS = no difference in 
pain reduction between 
PRP and HA (p>0.05)
S = PRP showed 
greater reduction 
in pain than HA 
(P<0.05) 
NS = no 
difference in pain 
reduction 
between PRP and 
HA (p>0.05)
S = PRP showed 
greater reduction 
in pain than HA 
(P<0.05) 
NS = no 
difference in pain 
reduction between 
PRP and HA 
(p>0.05)
S = PRP showed 
greater reduction 
in pain than HA 
(P<0.05) 
NS = no 
difference in pain 
reduction 
between PRP and 
HA (p>0.05)
S = PRP showed 
greater reduction 
in pain than HA 
(P<0.05) 
NS = no difference 
in pain reduction 
between PRP and 
HA (p>0.05)
S = PRP showed 
greater reduction in 
pain than HA 
(P<0.05) 
NS = no difference 
in pain reduction 
between PRP and 
HA (p>0.05)
S = PRP showed 
greater reduction in 
pain than HA 
(P<0.05) 
NS = no difference 
in pain reduction 
between PRP and 
HA (p>0.05)
S = PRP showed 
greater reduction 
in pain than HA 
(P<0.05) 
NS = no difference 
in pain reduction 
between PRP and 
HA (p>0.05)
S = PRP showed 
greater reduction 
in pain than HA 
(P<0.05) 
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